Adverse events in bedaquiline‐ and pretomanid‐based regimens for drug‐resistant tuberculosis from trial, implementation and pharmacovigilance studies
British Journal of Clinical Pharmacology · 2026-08 · 92 (8) · 2607-2623
DOI: 10.1002/bcp.70541 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift British Journal of Clinical Pharmacology, online erschienen am 12.05.2026. Verfasst von Nisa Maria und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Faculty of Medicine and Health, University of Sydney, Sydney, Australia. Hauptthemen laut MEDLINE: Diarylquinolines, Antitubercular Agents, Nitroimidazoles, Tuberculosis, Multidrug-Resistant. Die Arbeit nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Australia Awards.
Themen: Patientensicherheit
Abstract (Originalsprache)
The availability of safety data, particularly concerning adverse events (AEs) associated with the new shorter regimen for drug‐resistant tuberculosis (TB) containing a bedaquiline–pretomanid‐based regimen, is still limited. This systematic review aims to provide a comprehensive and updated analysis of AEs related to this new regimen by combining safety data from clinical trials, implementation and pharmacovigilance studies. We conducted a search using PubMed, Medline and Web of Science to identify studies that reported AE data for bedaquiline–pretomanid‐based regimens. In total, 14 studies from various countries were included in the analysis, comprising seven clinical trials, six implementation studies and one pharmacovigilance study. AE detection methods differed between clinical trials and implementation studies. Clinical trials utilised structured and standardised detection methods, whereas implementation and pharmacovigilance studies relied on spontaneous reporting with a higher prevalence of AEs reported in clinical trials (62.2–100%) compared to implementation studies (41.8–72.8%). Serious AEs developed in 2.2–30.2% of patients. Among those with serious AEs, 7.7–54.3% required interruption of TB drugs, while 3.5–13% required withdrawal of TB drugs. AE outcomes showed full recovery in 79.2%. However, 23–32% of patients reported AEs even after completing their treatment. Understanding AEs is crucial for healthcare professionals to enhance patient care, as early detection and appropriate management of AEs is essential in TB treatment to increase tolerability, minimise complications and optimise clinical outcomes. Further research is necessary to implement active monitoring for this new TB regimen in real‐world settings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Faculty of Medicine and Health, University of Sydney, Sydney, Australia.
- Faculty of Pharmacy, Universitas Indonesia, Depok, Indonesia.
- Sydney Infectious Diseases Institute, University of Sydney, Sydney, Australia.
- Westmead Hospital, Sydney, Australia.
- Departement of Pharmacy, Universitas Indonesia Hospital, Jawa Barat, Indonesia.
- Department of Respiratory and Sleep Medicine, Westmead Hospital, Sydney, Australia.
ORCID-Profile: Nisa Maria, Annisa Lazuardi Larasati, Indri Yuliani Hamdani, Jin-Gun Cho, Jan-Willem C Alffenaar
Förderung
- Australia Awards
Zitieren
APA
Maria, N., Larasati, A. L., Hamdani, I. Y., Cho, J. G., & Alffenaar, J. C. (2026). Adverse events in bedaquiline‐ and pretomanid‐based regimens for drug‐resistant tuberculosis from trial, implementation and pharmacovigilance studies. British Journal of Clinical Pharmacology, 92(8), 2607-2623. https://doi.org/10.1002/bcp.70541
Vancouver
Maria N, Larasati AL, Hamdani IY, Cho JG, Alffenaar JC. Adverse events in bedaquiline‐ and pretomanid‐based regimens for drug‐resistant tuberculosis from trial, implementation and pharmacovigilance studies. British Journal of Clinical Pharmacology. 2026;92(8):2607-2623. doi:10.1002/bcp.70541
BibTeX
@article{Maria2026,
author = {Maria, Nisa and Larasati, Annisa Lazuardi and Hamdani, Indri Yuliani and Cho, Jin-Gun and Alffenaar, Jan-Willem C},
title = {Adverse events in bedaquiline‐ and pretomanid‐based regimens for drug‐resistant tuberculosis from trial, implementation and pharmacovigilance studies},
journal = {British Journal of Clinical Pharmacology},
year = {2026},
volume = {92},
number = {8},
pages = {2607--2623},
doi = {10.1002/bcp.70541}
}
EUVIMED